搜索
Search
img

News Center

新闻中心

KX-826 Received The INCI Designation

KX-826 Received The INCI Designation

(Summary description)June 5, 2024-Kintor Pharmaceutical Limited announced that KX-826 received the INCI designation.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2024-06-05 16:00
  • Views:
Information

Suzhou, June 5, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed KX-826 has recently received the International Nomenclature Cosmetic Ingredient (the “INCI”) review approval from the International Cosmetic Ingredient Nomenclature Committee. The assigned INCI name is Methylpyridinyl Fluoromethoxybenzonitrile Dimethyloxothiooxoimidazolidine.

 

INCI names are systemic names recognized worldwide for the identification of cosmetic ingredients and are cited by product labeling regulations in many countries. The assignation would facilitate the global launch of the Company's functional cosmetics with KX-826 as the main ingredient.

Related documents

There is currently no content to display
Please add data record on website background.